Antiulcer and antimicrobial activity of Anogeissus latifolia.
Ethnobotanically, the bark of Anogeissus latifolia (Roxb. ex DC.) Wall. ex Guill. and Perr.(Combretaceae) has been reported to be used in the treatment of various disorders including stomach and skin diseases. We studied the antiulcer potential and antimicrobial activity of the 50% aqueous alcoholic extract in order to validate ethnobotanical claims regarding the plant use in the above-mentioned disorders. Gastroprotective potential of the Anogeissus latifolia extract (ALE) (100 and 200mg/kg/body weight) was studied on aspirin, cold-resistant stress (CRS), pylorus ligated (PL) and ethanol-induced ulcers. Status of the antioxidant enzymes superoxide dismutase (SOD) and catalase along with lipid peroxidation (LPO) was also studied in CRS-induced ulcers. The results of the present study showed for the first time that the ALE possessed gastroprotective activity as evidenced by its significant inhibition in the formation of ulcers induced by physical and chemical agents with a maximum of 84.16% curation (200mg/kg body weight) in CRS-induced ulcers. ALE decreased LPO and SOD with concomitant increase in catalase activity in CRS-induced ulcers. Moderate antibacterial activity and antifungal activity was also observed. High performance thin layer chromatography (HPTLC) showed the presence of gallic acid and ellagic acid (0.95%, w/w, 0.25%, w/w, respectively) in the plant. These findings could justify, at least partially, the inclusion of this plant in the management of gastric disorders in traditional medicine.
Govindarajan
R
R
Pharmacognosy and Ethnopharmacology Division, National Botanical Research Institute, Rana Pratap Marg, Lucknow 226 001, India.
Vijayakumar
M
M
Singh
M
M
Rao
Ch V
ChV
Shirwaikar
A
A
Rawat
A K S
AK
Pushpangadan
P
P
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000891:Anti-Infective Agents, Local / Q000633:toxicity; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000633:toxicity; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000633:toxicity; D001419:Bacteria / Q000187:drug effects* / Q000254:growth & development; D029764:Combretaceae / Q000737:chemistry*; D004353:Drug Evaluation, Preclinical; D004610:Ellagic Acid / Q000378:metabolism; D000431:Ethanol / Q000633:toxicity; D005707:Gallic Acid / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D008517:Phytotherapy; D024301:Plant Bark / Q000737:chemistry; D010936:Plant Extracts / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D013276:Stomach Ulcer / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D013482:Superoxide Dismutase / Q000378:metabolism
D000890:Anti-Infective Agents; D000891:Anti-Infective Agents, Local; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D010936:Plant Extracts; D004610:Ellagic Acid; D000431:Ethanol; D005707:Gallic Acid; D013482:Superoxide Dismutase; D001241:Aspirin